文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

甲磺酸阿帕替尼联合长春瑞滨对比长春瑞滨单药治疗复发或转移性三阴性乳腺癌的随机对照临床试验方案

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.
PubMed 文献 · Trials · 2020-05-24

本研究为三盲、随机、安慰剂对照、平行组临床试验,计划纳入238例局部复发或转移性三阴性乳腺癌女性患者,随机接受口服长春瑞滨单药或联合口服甲磺酸阿帕替尼治疗,主要终点为无进展生存期,次要终点包括总生存期、疾病控制率、客观缓解率及3/4级不良事件发生率。

要点

  • 针对既往接受过蒽环类和紫杉类治疗的复发或转移性TNBC女性患者。
  • 随机比较长春瑞滨单药与联合甲磺酸阿帕替尼的疗效与安全性。
  • 主要终点为无进展生存期,每6周进行影像学评估直至36周。

核心结论

  • 本试验旨在为东北地区既往接受过蒽环类和紫杉类治疗的TNBC女性患者寻找合适的治疗方案。

研究设计与样本

  • 三盲、随机、安慰剂对照、平行组临床试验,计划纳入238例局部复发或转移性TNBC女性患者。

关键数值与推荐

  • 口服长春瑞滨单药组:40 mg,每周三次(周一、周三、周五),每3周一个周期。
  • 联合组:口服长春瑞滨同上联合口服甲磺酸阿帕替尼500 mg,每日一次,每3周一个周期。
  • 主要终点为无进展生存期;次要终点包括总生存期、疾病控制率、客观缓解率及3/4级不良事件发生率。
  • 影像学评估每6周一次至36周,之后每9周一次;结局指标在基线、治疗中每6周、停药后4周及每3个月评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The emergence of new molecular targeted drugs provides new prospects for the treatment of advanced breast cancer; the future therapeutic trend includes chemotherapy combined with molecular targeted therapy. Apatinib mesylate, a novel, small anti-angiogenic agent, highly selectively inhibits the activity of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib mesylate also blocks the signaling of vascular endothelial growth factor binding to its receptor, thereby strongly inhibiting tumor angiogenesis and exerting an anti-tumor effect. However, there have been no reports of a randomized controlled clinical trial of apatinib combined with vinorelbine for the treatment of triple-negative breast cancer (TNBC). We will compare the therapeutic effect of vinorelbine alone or in combination with apatinib mesylate, in patients with recurrent or metastatic TNBC in North China who have received at least two drug treatments, including anthracyclines and taxanes. METHODS/ANALYSIS: This study is a triple-blind, randomized, placebo-controlled, parallel-group clinical trial. We plan to include 238 female patients with locally recurrent or metastatic TNBC, admitted to the Liaoning Cancer Hospital & Institute, Northeast China. All enrolled patients will be randomized to oral vinorelbine alone (40 mg, thrice a week (Mondays, Wednesdays, and Fridays) in each 3-week cycle), or in combination with oral apatinib mesylate (500 mg, once daily in each 3-week cycle). Radiographic assessment will be performed every 6 weeks for 36 weeks and every 9 weeks thereafter. The primary outcome is progression-free survival and secondary outcomes include overall survival, disease control rate, objective response rate, and incidence of adverse events at grades 3 and 4, as defined by the National Cancer Institute Common Toxicity Criteria Version 4.0. Outcome measures will be evaluated at baseline (< 2 weeks before starting treatment), every 6 weeks during treatment, and at 4 weeks and every 3 months after treatment discontinuation. DISCUSSION: Based on the data from this trial, we hope to identify a treatment plan that is suitable for female patients with TNBC, who have been treated with anthracyclines and taxanes, in Northeast China. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03932526. Registered on 30 April 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wu S, Zhang L, Li H, et al. Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial. Trials. 2020. PMID: 32448335. doi:10.1186/s13063-020-04342-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。